Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

10 June 2021

More research funding needed to avoid drug-resistant pandemic, warns report

Julia Kollewe for the Guardian covers the most recent report by the Access to Medicine Foundation.

Kollewe writes about the latest research from the Antimicrobial Resistance Benchmark Programme, which examines the financial challenges facing small drug-makers and impacts their ability to get new medicines to people who need them. 

The author explains how antibiotic overuse exacerbates AMR and how despite the great need for new medicines, small companies struggle to stay afloat in a difficult market. Quoting the report, Kollewe writes, "If the loss of such promising products continues, the pandemic of drug-resistant infections will pose a bigger global health emergency than Covid-19." 

Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, is quoted in the article: 
“Small and medium-sized companies are very critical for antimicrobial research. Big pharma has been leaving this space – only a small handful of companies are still developing drugs.”  Further, Jayasree explains, partnerships between countries can help incentivise small drug-makers to sustain efforts to produce new medicines.

Click to read the full article. 

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved